Genistein causes regression of endometriotic implants in the rat model.
OBJECTIVE
To determine the effects of raloxifene and genistein on experimentally induced endometriosis in a rat model.


METHODS
Prospective, randomized animal study.


METHODS
Animal surgery laboratory in a university hospital.


METHODS
Thirty-three adult, mature female Wistar-Albino rats in which endometriotic implants were induced by transplanting autologous uterine tissue to ectopic sites on the peritoneum.


METHODS
After the endometriotic implants were formed surgically, the 33 rats were randomly divided into three groups. Group 1 (genistein group, 10 rats) were given 500 mg/kg per day of oral genistein. Group 2 (raloxifene group, 10 rats) were given 10 mg/kg per day of oral raloxifene. Group 3 were given no medication and served as controls (13 rats). All the rats continued to receive treatment for 21 days, and then were killed to assess the implants' size and for histologic examination.


METHODS
The surface area of the endometriotic implants and the score of histologic analysis.


RESULTS
At the beginning of the medical treatment, the mean surface areas of the endometriotic implants were comparable in all three groups. At the end of the medical treatment, the mean surface area of implants in groups 1 and 2 was smaller than that of implants in the control group. The decrease in the surface area of the endometriotic implants was greater in group 1 and group 2 than found in the control group. The histologic assessment revealed that the mean of the histopathologic score of the implants at the end of the treatment was lower in groups 1 and 2 when compared with the control group.


CONCLUSIONS
Genistein caused a statistically significant regression of endometriotic implants.
Yavuz
Emrah
E
Department of Obstetrics and Gynecology, Baskent University Faculty of Medicine, Ankara, Turkey.
Oktem
Mesut
M
Esinler
Ibrahim
I
Toru
Serap Arat
SA
Zeyneloglu
Hulusi B
HB
D000818:Animals; D004195:Disease Models, Animal; D004353:Drug Evaluation, Preclinical; D004715:Endometriosis / Q000188:drug therapy / Q000473:pathology* / Q000517:prevention & control*; D004717:Endometrium; D005260:Female; D019833:Genistein / Q000627:therapeutic use*; D010529:Peritoneal Cavity; D011446:Prospective Studies; D011897:Random Allocation; D051381:Rats; D017208:Rats, Wistar
D019833:Genistein